Description Overview Dihexa (also referred to as PNB-0408
The degradation rate and half-life (t1/2) of the drugs were determined by measuring the decrease in area under the curve (AUC) at their retention times [1]
Unlike standard nootropics, which temporarily alter neurotransmitter activity, Dihexa promotes long-lasting structural improvements in brain connectivity and cognitive performance
2) This review completed by Wright et al investigates the development of small molecule AngIV analogs as potential treatments for AD and PD, two debilitating neurodegenerative conditions currently lacking effective disease-modifying therapies
This effort led to the development of Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide), a key focus of this study [2]
Additionally, in order to explore the mechanism of action being neuronal apoptosis, the research team assessed levels of neuroinflammation and glial activation by detecting levels of IL-1-beta, IL-10, and TNF-alpha in the brain